加拿大不列颠哥伦比亚省痛风患病率与发病率上升趋势(2000–2012年)
该研究基于PopulationData BC全省数据库,估计2000至2012年加拿大不列颠哥伦比亚省痛风的患病率与发病率,并分析降尿酸治疗处方模式及合并症负担。2012年痛风患病率为3.8%,发病率为2.9/1000人年,两者在研究期间均显著上升,而降尿酸治疗处方率仅约22%且保持稳定。研究认为该省痛风负担沉重,需改善痛风的预防与诊疗。
要点
- 2012年全省痛风患病率3.8%,发病率2.9/1000人年,研究期内均明显上升。
- 60–69岁人群2012年痛风患病率超过8%,负担随年龄增加而升高。
- 仅约22%痛风患者接受降尿酸治疗,研究期内保持稳定;秋水仙碱与口服糖皮质激素使用小幅增加。
核心结论
- 加拿大不列颠哥伦比亚省痛风负担沉重,患病率与发病率在过去十年均上升,而降尿酸治疗处方率仍处于低位,支持改进痛风预防与诊疗的必要性。
研究设计与样本
- 基于PopulationData BC全省数据库的 population-based 研究,估计2000至2012年痛风患病率与发病率的随时间趋势及按年龄分组的趋势,年度估计以2012年为参照进行年龄-性别标准化。
- 同时分析常见痛风药物处方模式的年度趋势,并评估2012年痛风患者的合并症负担。
主要发现
- 2012年总体人群痛风患病率为3.8%,发病率为2.9/1000人年,研究期内患病率与发病率均大幅上升。
- 痛风负担随年龄组增加而升高,2012年60–69岁人群患病率超过8%。
- 约22%的痛风患者获得降尿酸治疗处方,该比例研究期内保持稳定,而秋水仙碱和口服糖皮质激素使用均小幅增加。
- 至2012年,现患痛风患者中分别有72%、52%和18%被诊断为高血压、高脂血症和糖尿病。
临床怎么用
- 提示临床应关注痛风患病率与发病率上升趋势,尤其在老年人群中加强筛查与长期管理。
- 降尿酸治疗处方率仅约22%,提示需提高符合指征患者的降尿酸治疗覆盖率。
- 痛风患者合并高血压、高脂血症、糖尿病比例高,诊疗中应重视合并症评估与综合管理。
局限性
- 研究基于行政数据库,痛风诊断依赖数据库记录,可能存在错分;处方数据仅反映开具行为,不能反映服药依从性;研究对象限于加拿大不列颠哥伦比亚省,外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Gout is increasingly recognized as the most common form of inflammatory arthritis worldwide; however, no Canadian data on the disease burden of gout are available. We estimated the prevalence, incidence, prescription patterns, and comorbidity burden of gout in an entire Canadian province [British Columbia (BC)] over the last decade. METHODS: We utilized PopulationData BC, a province-wide database, to estimate temporal trends in the prevalence and incidence of gout from 2000 to 2012, as well as according to age category. Annual estimates were age-sex-standardized using 2012 as the reference. We also examined annual trends in prescription patterns of common gout medications and assessed the comorbidity burden among gout patients in 2012. RESULTS: The 2012 prevalence of gout was 3.8% among the overall population, and the incidence rate was 2.9 per 1000 person-years. Both gout prevalence and incidence increased substantially over the study period. This burden additionally increased according to age category, affecting over 8% of those ages 60-69 years in 2012. Approximately 22% of gout patients received a prescription for urate-lowering therapy (ULT), which remained stable over the study period, while colchicine and oral glucocorticoid use both increased modestly. By 2012, 72%, 52%, and 18% of prevalent gout patients had been diagnosed with hypertension, hyperlipidemia, and diabetes, respectively. CONCLUSIONS: The burden of gout in BC, Canada, is substantial, and both the prevalence and incidence have increased over the past decade, while prescription of ULT remains low. These data support the need to improve gout prevention and care.
引用
- Rai SK, Aviña-Zubieta JA, McCormick N, et al. The rising prevalence and incidence of gout in British Columbia, Canada: Population-based trends from 2000 to 2012. Semin Arthritis Rheum. 2016. PMID: 28040245. doi:10.1016/j.semarthrit.2016.08.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。